Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring
CA 2129679 C · Owner: Aslanian, Robert · Inventors: Aslanian, Robert; Lupo, Andrew Jr.; Ganguly, Ashit K.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed is a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof. Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of a compound of formula (I). Further disclosed is a method of treating allergy (for example asthma) inflammation, hypertension, raised intraocular pressure (such as glaucoma)--i.e. a method of lowering intraocular pressure sleeping , disorders, states of hyper and hypo motility and acidic secretion of the gastrointestinal tract hypo and hyerpactivity of the , central nervous system (for example agitation and , depression) and other CNS disorders (such as Alzheimers …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 17, 1992 and granted May 9, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 17, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 17, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.